venetoclax,quizartinib,decitabine
roche,abbvie,daiichi sankyo
['leusm', 'triplet', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)']
congress | #eha2022 | musa yilmaz, , presented phase i/ii data on dac + ven + quiz triplet in pts with flt3-itdm #aml. 23/28 pts with r/r aml achieved crc and all 7 pts with nd aml achieved crc. pts with underlying ras/mapk mutations had lower response rates #leusm 
The AML Hub is an evidence-based online resource on Acute Myeloid Leukemia (AML), for academic researchers and treating clinicians. #leusm